deltatrials
Completed PHASE2/PHASE3 NCT00240383

Dose Ranging Study With LT, Monotherapy, PPAR

A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes

Sponsor: Bristol-Myers Squibb

Conditions Diabetes Mellitus II
Interventions Muraglitazar
Updated 7 times since 2017 Last updated: Sep 10, 2010 Started: May 31, 2002 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

Listed as NCT00240383, this PHASE2/PHASE3 trial focuses on Diabetes Mellitus II and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2_PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico, Albens, France, Albuquerque, United States, Anderson, United States, Annan, United Kingdom, Anniston, United States, Arden Hills, United States, Arkansas City, United States, Atherstone, United Kingdom, Atlanta, United States and 254 more location s